- Home
- KROS vs GMRE Comparison
KROS vs GMRE Comparison
Compare KROS & GMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- GMRE
- Stock Information
- Founded
- KROS 2015
- GMRE 2011
- Country
- KROS United States
- GMRE United States
- Employees
- KROS N/A
- GMRE N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- GMRE Real Estate Investment Trusts
- Sector
- KROS Health Care
- GMRE Real Estate
- Exchange
- KROS Nasdaq
- GMRE Nasdaq
- Market Cap
- KROS 565.0M
- GMRE 485.5M
- IPO Year
- KROS 2020
- GMRE N/A
- Fundamental
- Price
- KROS $14.51
- GMRE $6.94
- Analyst Decision
- KROS Buy
- GMRE Buy
- Analyst Count
- KROS 13
- GMRE 3
- Target Price
- KROS $20.63
- GMRE $10.38
- AVG Volume (30 Days)
- KROS 450.7K
- GMRE 723.5K
- Earning Date
- KROS 08-06-2025
- GMRE 08-05-2025
- Dividend Yield
- KROS N/A
- GMRE 12.10%
- EPS Growth
- KROS N/A
- GMRE N/A
- EPS
- KROS 0.11
- GMRE 0.03
- Revenue
- KROS $214,713,000.00
- GMRE $138,220,000.00
- Revenue This Year
- KROS $5,390.70
- GMRE $4.47
- Revenue Next Year
- KROS N/A
- GMRE $3.60
- P/E Ratio
- KROS $133.17
- GMRE $216.81
- Revenue Growth
- KROS 91657.70
- GMRE N/A
- 52 Week Low
- KROS $9.12
- GMRE $6.06
- 52 Week High
- KROS $72.37
- GMRE $10.46
- Technical
- Relative Strength Index (RSI)
- KROS 58.66
- GMRE 48.95
- Support Level
- KROS $14.18
- GMRE $7.07
- Resistance Level
- KROS $14.85
- GMRE $7.28
- Average True Range (ATR)
- KROS 0.55
- GMRE 0.15
- MACD
- KROS 0.04
- GMRE -0.04
- Stochastic Oscillator
- KROS 71.78
- GMRE 34.91
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About GMRE Global Medical REIT Inc.
Global Medical REIT Inc is engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.